FDA Approves RELEUKO — Amneal Pharmaceuticals LLC

Amneal Pharmaceuticals announced the FDA approval of its intravenousfilgrastim injection under the brand name RELEUKO, positioning the company to expand its biologics portfolio as a potential alternative to legacy compression products in the inhaled market. The move allows Amneal to compete with current leaders like Pfizer’s Neulasta and Gilead’s Kosmicoz, potentially pressuring market pricing and bolstering its revenue share within the oncology supportive care sector.